Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk
Olanzapine (Zyprexa), an atypical antipsychotic, is used off-label for managing nausea in advanced cancer patients but is linked to severe metabolic side effects, including hypertriglyceridemia. This case involves a metastatic gastric carcinoma patient with no known metabolic disorder who developed...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621924000668 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Olanzapine (Zyprexa), an atypical antipsychotic, is used off-label for managing nausea in advanced cancer patients but is linked to severe metabolic side effects, including hypertriglyceridemia. This case involves a metastatic gastric carcinoma patient with no known metabolic disorder who developed critically elevated triglycerides (2898 mg/dL) after starting olanzapine for nausea. Her lipid levels significantly improved with medical management, allowing her to proceed for apheresis for the planned CAR-T treatment. This case underscores the need for vigilant metabolic monitoring in patients on Olanzapine (Zyprexa), even those without known risk factors, to prevent serious complications. |
|---|---|
| ISSN: | 2666-6219 |